NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study.

Sarcopenia is associated with NAFLD. It is unknown if the association is explained by shared risk factors. Our study sought to investigate the association between liver fat and sarcopenia in our cohort.

Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease.

The association between the pathogenesis and natural course of nonalcoholic fatty liver disease (NAFLD) and skeletal muscle dysfunction is increasingly recognized. These obesity-associated disorders originate primarily from sustained caloric excess, gradually disrupting cellular and molecular mechanisms of the adipose-muscle-liver axis resulting in end-stage tissue injury exemplified by cirrhosis and sarcopenia. These major clinical phenotypes develop through complex organ-tissue interactions from the earliest stages of NAFLD.

Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota.

Purpose Of Review: This review specifically explores the affect that diet has on the gut microbiota and its role on the increasing incidence of IBD around the world in developing countries.

Recent Findings: This is a The emergence of IBD is consistently observed as a society becomes developed and westernized implicating the critical role that environmental factors play. Environmental factors that could play a significant role in the pathogenesis of IBD include westernization of diet and improved hygiene statust.

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.

Background: In 2016, the FDA approved infliximab-dyyb (IFX-dyyb) as a biosimilar to infliximab (IFX). Deemed to have comparable efficacy and safety to IFX, IFX-dyyb is 20%-30% less expensive, allowing significant cost savings for institutions and some payers. In 2018, IFX was reported to be the drug with the highest spend since 2013, costing $3.

Trends in total ankle arthroplasty and revisions in the Medicare database.

Background: High failure rates and unacceptable patient outcomes have kept total ankle arthroplasty (TAA) from becoming a favorable treatment option. Modern prosthetic designs and techniques have improved outcomes and decreased revision rates. Current literature has not adequately investigated the recent trends in TAA utilization and revision rate.